Laminin-111 – Revolutionary Treatment for MDC1A (LAMA2 Deficiency)

Recombinant human Laminin-111 (rhLAM-111) is an intravenous protein replacement for deficiency of LAM-211 (LAMA2)

Replaces all LAMA2 functions – clear mechanism of action

Will transform patients into walking independent children

Dominates all other approaches for MDC1A

Non-immunogenic therapy – drug half-life in muscle is > 1 month

$750M annual sales 5 years post approval

Cerezyme-like market endurance and patient loyalty



  • Bradley Hodges PhD, Founder, CSO
  • Richard Cloud MBA, CEO, Co-founder CureCMD


  • Alan Beggs PhD, Boston Children’s
  • Dean Burkin PhD, Inventor of LAM-111, UNR
  • Kay Davies PhD CBE DBE F.MedSci. FRS, Oxford
  • Madde Durbeej PhD, Lund University
  • Paul Martin PhD, Nationwide Children’s
  • Lee Sweeney PhD, Florida


  • Lee Bussey PhD
  • Becky Dabora PhD
  • Beth Goad DVM PhD
  • Sherry Martin-Moe PhD
  • Mike Ultee PhD


Laminin-111 MOA

rhLAM-111 and the missing LAM-211 protein are structurally and functionally the most similar among ~17 different isoforms of laminin

rhLAM-111 fully replicates all functions of the missing LAM-211 protein

rhLAM-111 is expressed in all humans and therefore will be non-immunogenic to MDC1A patients

Intravenous rhLAM-111 targets skeletal and cardiac muscle through high affinity binding to two critical laminin receptors – alpha7 integrin and alpha dystroglycan

rhLAM-111 deposits on the muscle surface and rebuilds the extracellular matrix

Muscle apoptosis, inflammation, fibrosis, adipogenesis and paralysis are blocked by rhLAM-111

rhLAM-111 stimulates satellite stem cells to regenerate new muscle

Prothelia’s rhLAM-111 approach for MDC1A is similar to utrophin replacement for Duchenne muscular dystrophy

Prothelia Corporate Presentation

Our corporate and scientific summary is available here.

Dr. Bradley Hodges and Rich Cloud to attend the CureCMD Scientific & Family Conference, July 25-28, 2019
Dr. Bradley Hodges and Rich Cloud to attend JPM January 8th – 10th, 2019
Dr. Bradley Hodges will be attending the New Directions in Biology and Disease of Skeletal Muscle Conference held in New Orleans, LA June 25-28, 2018


Prothelia Incorporated

30 Haven Street

Milford, MA 01757